Skip to main content

LDX

When I last looked at Lumos Diagnostic (ASX: LDX) was in April when they were at 2 cents and I said that they were one worth attention. Well, going from there to 28 cents is a phenomenal result for 8 months. Do they have further to go? Absolutely. The fundamentals of this company haven't changed and I expect them to keep going and going. The thing that they really face is the possibility of a takeover as the major pharma companies dip their toes over the edge of the patent cliff.

That can only mean a good opportunity for existing shareholders.

I will look back in April to see how they are going.

Comments

Popular posts from this blog

BOT

 As far as quarterly announcements go, the one out today from BOT is one of the nest I have ever seen. And it only get beaten by the next quarterly. The only way this stock is going is up - with the potential of a takeover offer (nothing is certain).

It's 31 Jan

 And that means we will hear about the AAR T/O offer of MXR today or tomorrow. Considering that MXR have not been sitting idle while AAR have been going through the data, I would like to think that the offer will be increased. Already the offer is at 7 cents (AAR scrip equivalent) in a share swap - no you don't get the cash, you get the shares in AAR. As I wrwite this, MXR is still at 6.3 cents, so there could be a quick profit to be made for those who can jump fast.

A Couple of Updates

 Well, it's Monday morning and the week has started with a bang. First, PFE announced that there was an unexpected problem with their test drill and they have had to abandon that and go to a new test drill site. A delay, but no real issue apart from that. And the market hated that. Good news for those wanting to buy, not so good for existing holders. IMC released their AGM presentation which indicates that there will be some news in December and then a very busy (and hopefully productive) 2025. Sales are good and continuing to get better and better.